OBJECTIVES: There is scarce data about effects of treatment of clinical depression in peritoneal dialysis (PD) population. We aimed to determine prevalence of depression, its association with health-related quality of life (HRQoL) and effects of sertraline treatment in PD patients. MATERIALS AND METHODS: We included 124 PD patients who had been on PD at least for 6 months. Short Form of Medical Outcomes Study was used to evaluate HRQoL. Depression was screened by Beck Depression Inventory (BDI). Patients with a BDI score > or = 17 were deemed to have depression and were referred to a psychiatrist for evaluation via Diagnostic and Statistical Manual for Mental Disorders (DSM-IV) of diagnosis of clinical depression. About 25 patients diagnosed with clinical depression agreed to receive antidepressant treatment (Sertraline hydrochloride, 50 mg/day) for a 12-week period. After the treatment, biochemical analyses and questionnaires were repeated. RESULTS: Thirty-two patients (25.8%) had depression. BDI score of patients were lower compared to those without depressive symptoms (23 + or - 6.7 and 9.8 + or - 3.0, respectively P < 0.001). Physical component scale (PCS) and mental component scale (MCS) domains of HRQoL were significantly decreased in patients with depression than in patients without depression (P < 0.001 for PCS and MCS). In bivariate analysis the BDI score was correlated inversely with the PCS and MCS (P < 0.001). Sertraline treatment improved BDI score of patients with depression (P < 0.001). HRQoL parameters also improved. No adverse effects requiring drug cessation was seen in the study group. CONCLUSIONS: Treatment of depression with sertraline is associated with improvement of the HRQoL and symptoms related to depression.
OBJECTIVES: There is scarce data about effects of treatment of clinical depression in peritoneal dialysis (PD) population. We aimed to determine prevalence of depression, its association with health-related quality of life (HRQoL) and effects of sertraline treatment in PDpatients. MATERIALS AND METHODS: We included 124 PDpatients who had been on PD at least for 6 months. Short Form of Medical Outcomes Study was used to evaluate HRQoL. Depression was screened by Beck Depression Inventory (BDI). Patients with a BDI score > or = 17 were deemed to have depression and were referred to a psychiatrist for evaluation via Diagnostic and Statistical Manual for Mental Disorders (DSM-IV) of diagnosis of clinical depression. About 25 patients diagnosed with clinical depression agreed to receive antidepressant treatment (Sertraline hydrochloride, 50 mg/day) for a 12-week period. After the treatment, biochemical analyses and questionnaires were repeated. RESULTS: Thirty-two patients (25.8%) had depression. BDI score of patients were lower compared to those without depressive symptoms (23 + or - 6.7 and 9.8 + or - 3.0, respectively P < 0.001). Physical component scale (PCS) and mental component scale (MCS) domains of HRQoL were significantly decreased in patients with depression than in patients without depression (P < 0.001 for PCS and MCS). In bivariate analysis the BDI score was correlated inversely with the PCS and MCS (P < 0.001). Sertraline treatment improved BDI score of patients with depression (P < 0.001). HRQoL parameters also improved. No adverse effects requiring drug cessation was seen in the study group. CONCLUSIONS: Treatment of depression with sertraline is associated with improvement of the HRQoL and symptoms related to depression.
Authors: Peter H Juergensen; Alexander Zemchenkov; Susan Watnick; Susan Finkelstein; Diane Wuerth; Fredric O Finkelstein Journal: Adv Perit Dial Date: 2002
Authors: T E Steele; D Baltimore; S H Finkelstein; P Juergensen; A S Kliger; F O Finkelstein Journal: J Nerv Ment Dis Date: 1996-06 Impact factor: 2.254
Authors: S Susan Hedayati; Hayden B Bosworth; Libbie P Briley; Richard J Sloane; Carl F Pieper; Paul L Kimmel; Lynda A Szczech Journal: Kidney Int Date: 2008-06-25 Impact factor: 10.612
Authors: Laura Troidle; Suzanne Watnick; Diane B Wuerth; Nancy Gorban-Brennan; Alan S Kliger; Fredric O Finkelstein Journal: Am J Kidney Dis Date: 2003-08 Impact factor: 8.860
Authors: Linda Y Belayev; Maria K Mor; Mary Ann Sevick; Anne Marie Shields; Bruce L Rollman; Paul M Palevsky; Robert M Arnold; Michael J Fine; Steven D Weisbord Journal: Hemodial Int Date: 2014-11-18 Impact factor: 1.812
Authors: S Susan Hedayati; Divya M Daniel; Scott Cohen; Bryan Comstock; Daniel Cukor; Yaminette Diaz-Linhart; Laura M Dember; Amelia Dubovsky; Tom Greene; Nancy Grote; Patrick Heagerty; Wayne Katon; Paul L Kimmel; Nancy Kutner; Lori Linke; Davin Quinn; Tessa Rue; Madhukar H Trivedi; Mark Unruh; Steven Weisbord; Bessie A Young; Rajnish Mehrotra Journal: Contemp Clin Trials Date: 2015-11-24 Impact factor: 2.226
Authors: Mark L Unruh; Brett Larive; Glenn M Chertow; Paul W Eggers; Amit X Garg; Jennifer Gassman; Maria Tarallo; Fredric O Finkelstein; Paul L Kimmel Journal: Am J Kidney Dis Date: 2013-01-15 Impact factor: 8.860
Authors: S Susan Hedayati; L Parker Gregg; Thomas Carmody; Nishank Jain; Marisa Toups; A John Rush; Robert D Toto; Madhukar H Trivedi Journal: JAMA Date: 2017-11-21 Impact factor: 56.272